Metastatic Endometrial Cancer
9 clinical trials · Condition
◉ Watch Metastatic Endometrial Cancer
| Record | Firm | Date |
|---|---|---|
| Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer (NCT04906382) | Floor Backes, MD | 2021-07-01 |
| Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer (NCT03617679) | University of Colorado, Denver | 2019-03-06 |
| Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer (NCT03277482) | Dana-Farber Cancer Institute | 2018-06-01 |
| Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer (NCT02912572) | Dana-Farber Cancer Institute | 2016-11-14 |
Track Metastatic Endometrial Cancer automatically
Every clearance here is in the API, with alerts when new ones post.